ImmuneRegen BioSciences, Inc. Founder, Director and Head Researcher, Dr. Mark Witten, Interviewed About Rapid Response Team and Stockpile Therapies in Event of Bioterrorism Attack
ImmuneRegen Executive discusses Rapid Response Team and Stockpile Therapies in Event of Bioterrorism Attack
Scottsdale, AZ (PRWEB) September 9, 2004 -- Dr. Mark Witten, Chief Scientist
for ImmuneRegen BioSciences, Inc., (OTC BB: IRBO), was interviewed by CBS
affiliate KOLD-TV and ABC affiliate KGUN-TV in Tucson, concerning the hovering
threat of bioterrorism at the Republican National Convention as well as in and
around the U.S. in the coming decade.
During the interviews, Dr. Witten
indicated that the company’s goal is to stockpile its proprietary compound
“Homspera” and have it ready to offer the government in an emergency situation
to treat the detriments associated with a potential “dirty bomb” or radioactive
terrorism. Homspera can potentially reverse damage caused by exposure to acute
radiation.
Anyone who would like a CD of aired interviews may make a
request by email to e-mail protected from spam bots
About ImmuneRegen
BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of
IR BioSciences Holdings, Inc. (OTC BB: IRBO), is a biotechnology company engaged
in the research and development of applications utilizing modified Substance P,
a naturally occurring immunomodulator. Derived from homeostatic substance P, the
company has named their proprietary compound "Homspera." The Company's initial
focus is on the continuing development of Homspera for various applications for
use in improving pulmonary function and stimulating the human immune system. For
more information, please visit the company's website at
www.immuneregen.com.
About Homspera
ImmuneRegen's patents and
continued substance P research are derived from discoveries made during research
funded by the Air Force Office of Scientific Research in the early 1990s. During
this research, Dr. Witten and his associates observed that the exposure of
animals to jet fuels resulted in pathological changes in the lung and immune
systems of those exposed. It was also observed that such exposure resulted in
depletion of substance P from the lungs of the animals. These studies further
showed that the administration of substance P may help prevent and reverse the
effects of jet fuel exposure in the lungs, as well as protect and regenerate the
immune system. The immune findings led to early research on the treatment of
exposure to acute radiation and on the possible reversal of lung damage caused
by ARDS and cigarette smoke.
Statements about the Company's future
expectations, including future revenues and earnings, and all other statements
in this press release other than historical facts, are "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934, and as that term is defined
in the Private Securities Litigation Reform Act of 1995. The Company intends
that such forward-looking statements be subject to the safe harbors created
thereby. The Company's actual results could differ materially from expected
results as a result of a number of factors, including the uncertainties inherent
in research collaborations, clinical trials and product development programs,
the evaluation of potential opportunities, the level of corporate expenditures,
capital market conditions, and others set forth in the Company’s SEC
filings.
# # #
Source : http://www.prweb.com/releases/2004/9/prweb155921.htm